The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis

Multiple Sclerosis

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Sorensen, P S ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Clinical trials; Gadolinium enhancing lesions; Gammaglobulin G; Intravenous immunoglobulin; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE; IMMUNOGLOBULIN G;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE;

EID: 0033758275     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245850000602s04     Document Type: Conference Paper

References (11)

1. Intravenous immunoglobulin G therapy: Effects of acute and chronic treatment in multiple sclerosis
2. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group
3. Intravenous immuglobin G reduces MRI activity in relapsing multiple sclerosis
4. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group
6. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
7. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
8. Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis
9. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group
10. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group
11. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group